AMD 070
| Title | Journal |
|---|---|
| The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. | Biochemical pharmacology 20120215 |
| Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. | Leukemia 20110801 |
| Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. | Bioorganic & medicinal chemistry letters 20110301 |
| HIV-1 tropism. | Protein & cell 20100601 |
| Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. | Bioorganic & medicinal chemistry letters 20100515 |
| Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. | Journal of medicinal chemistry 20100422 |
| Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. | Bioorganic & medicinal chemistry letters 20090901 |
| Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. | Molecular pharmacology 20081201 |
| Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. | Journal of acquired immune deficiency syndromes (1999) 20080415 |
| Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. | Antimicrobial agents and chemotherapy 20070701 |
| Emerging anti-HIV drugs. | Expert opinion on emerging drugs 20050501 |
| The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. | Drugs 20050101 |
| Emerging drug targets for antiretroviral therapy. | Drugs 20050101 |
| HIV co-receptor drugs on the horizon. | GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101 |